文献速递肿瘤 PET/CT核素与放射性配体治疗

61Cu-PSMA靶向PET用于前列腺癌:从放射性示踪剂开发到首次人体显像

61Cu-PSMA-Targeted PET for Prostate Cancer: From Radiotracer Development to First-in-Human Imaging.
PubMed 文献 · J Nucl Med · 2024-09-03

研究开发了61Cu标记的PSMA-I&T衍生物(DOTAGA-PSMA-I&T和NODAGA-PSMA-I&T),在体外和LNCaP异种移植模型中与[68Ga]Ga-PSMA-11和[18F]PSMA-1007比较,并计算了[61Cu]Cu-NODAGA-PSMA-I&T的人体剂量学,在一例转移性前列腺癌患者中完成首次人体显像,显示多灶性骨和肝转移。

要点

  • 61Cu可由回旋加速器大规模生产,3.33小时半衰期支持远距离运输。
  • [61Cu]Cu-NODAGA-PSMA-I&T在注射后1小时和4小时的肿瘤摄取高于[61Cu]Cu-DOTAGA-PSMA-I&T。
  • 首次人体显像显示多灶性骨和肝转移,[61Cu]Cu-NODAGA-PSMA-I&T有前景。

核心结论

  • [61Cu]Cu-NODAGA-PSMA-I&T是一种有前景的PSMA放射性示踪剂,与[68Ga]Ga-PSMA-11和[18F]PSMA-1007相比具有优势,同时允许延迟显像。

研究设计与样本

  • 研究在LNCaP细胞和异种移植瘤中进行体外和体内实验,比较61Cu标记的DOTAGA-PSMA-I&T和NODAGA-PSMA-I&T与[68Ga]Ga-DOTAGA-PSMA-I&T、[68Ga]Ga-NODAGA-PSMA-I&T、[68Ga]Ga-PSMA-11和[18F]PSMA-1007,并计算[61Cu]Cu-NODAGA-PSMA-I&T的人体剂量学,在一例转移性前列腺癌患者中进行首次人体显像。

主要发现

  • [61Cu]Cu-DOTAGA-PSMA-I&T和[61Cu]Cu-NODAGA-PSMA-I&T的放射化学纯度超过97%,表观摩尔活度为24 MBq/nmol,标记后无需纯化。
  • 天然Cu-DOTAGA-PSMA-I&T和天然Cu-NODAGA-PSMA-I&T对PSMA的半数抑制浓度分别为11.2 ± 2.3和9.3 ± 1.8 nM,高于天然Ga-PSMA-11的2.4 ± 0.4 nM。
  • 注射后1小时,[61Cu]Cu-NODAGA-PSMA-I&T的肿瘤摄取为14.0 ± 5.0 %IA/g,高于[61Cu]Cu-DOTAGA-PSMA-I&T的6.06 ± 0.25 %IA/g(P = 0.0059)。
  • 注射后1小时,[61Cu]Cu-NODAGA-PSMA-I&T的肿瘤摄取与[68Ga]Ga-PSMA-11的10.2 ± 1.5 %IA/g(P = 0.0972)和[18F]PSMA-1007的9.70 ± 2.57 %IA/g(P = 0.080)相比未达统计学显著。
  • 注射后4小时,[61Cu]Cu-NODAGA-PSMA-I&T的肿瘤摄取为10.7 ± 3.3 %IA/g,高于[61Cu]Cu-DOTAGA-PSMA-I&T的4.88 ± 0.63 %IA/g(P = 0.0014)和[18F]PSMA-1007的6.28 ± 2.19 %IA/g(P = 0.0145)。

关键数值与推荐

  • [61Cu]Cu-DOTAGA-PSMA-I&T和[61Cu]Cu-NODAGA-PSMA-I&T的放射化学纯度超过97%,表观摩尔活度为24 MBq/nmol。
  • 天然Cu-DOTAGA-PSMA-I&T和天然Cu-NODAGA-PSMA-I&T的半数抑制浓度分别为11.2 ± 2.3和9.3 ± 1.8 nM,天然Ga-PSMA-11的半数抑制浓度为2.4 ± 0.4 nM。
  • [61Cu]Cu-NODAGA-PSMA-I&T注射后1小时肿瘤摄取为14.0 ± 5.0 %IA/g,[61Cu]Cu-DOTAGA-PSMA-I&T为6.06 ± 0.25 %IA/g(P = 0.0059)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The demand for PET tracers that target prostate-specific membrane antigen (PSMA) continues to increase. Meeting this demand with approved 68Ga- and 18F-labeled PSMA tracers is challenging outside of major urban centers. This is because the short physical half-life of these radionuclides makes it necessary to produce them near their sites of usage. To overcome this challenge, we propose cyclotron-produced 61Cu for labeling PSMA PET tracers. 61Cu can be produced on a large scale, and its 3.33-h half-life allows shipping over considerably longer distances than possible for 68Ga and 18F. Production of true theranostic twins using 61Cu and the β--emitter 67Cu is also feasible. Methods: PSMA-I&T (DOTAGA-(l-y)fk(sub-KuE)) and its derivative in which the DOTAGA chelator was replaced by NODAGA (NODAGA-(l-y)fk(sub-KuE)), herein reported as DOTAGA-PSMA-I&T and NODAGA-PSMA-I&T, respectively, were labeled with 61Cu and compared with [68Ga]Ga-DOTAGA-PSMA-I&T, [68Ga]Ga-NODAGA-PSMA-I&T, [68Ga]Ga-PSMA-11, and [18F]PSMA-1007. In vitro (lipophilicity, affinity, cellular uptake, and distribution) and in vivo (PET/CT, biodistribution, and stability) studies were performed in LNCaP cells and xenografts. Human dosimetry estimates were calculated for [61Cu]Cu-NODAGA-PSMA-I&T. First-in-human imaging with [61Cu]Cu-NODAGA-PSMA-I&T was performed in a patient with metastatic prostate cancer. Results: [61Cu]Cu-DOTAGA-PSMA-I&T and [61Cu]Cu-NODAGA-PSMA-I&T were synthesized with radiochemical purity of more than 97%, at an apparent molar activity of 24 MBq/nmol, without purification after labeling. In vitro, natural Cu (natCu)-DOTAGA-PSMA-I&T and natCu-NODAGA-PSMA-I&T showed high affinity for PSMA (inhibitory concentration of 50%, 11.2 ± 2.3 and 9.3 ± 1.8 nM, respectively), although lower than the reference natGa-PSMA-11 (inhibitory concentration of 50%, 2.4 ± 0.4 nM). Their cellular uptake and distribution were comparable to those of [68Ga]Ga-PSMA-11. In vivo, [61Cu]Cu-NODAGA-PSMA-I&T showed significantly lower uptake in nontargeted tissues than [61Cu]Cu-DOTAGA-PSMA-I&T and higher tumor uptake (14.0 ± 5.0 percentage injected activity per gram of tissue [%IA/g]) than [61Cu]Cu-DOTAGA-PSMA-I&T (6.06 ± 0.25 %IA/g, P = 0.0059), [68Ga]Ga-PSMA-11 (10.2 ± 1.5 %IA/g, P = 0.0972), and [18F]PSMA-1007 (9.70 ± 2.57 %IA/g, P = 0.080) at 1 h after injection. Tumor uptake was also higher for [61Cu]Cu-NODAGA-PSMA-I&T at 4 h after injection (10.7 ± 3.3 %IA/g) than for [61Cu]Cu-DOTAGA-PSMA-I&T (4.88 ± 0.63 %IA/g, P = 0.0014) and [18F]PSMA-1007 (6.28 ± 2.19 %IA/g, P = 0.0145). Tumor-to-nontumor ratios of [61Cu]Cu-NODAGA-PSMA-I&T were superior to those of [61Cu]Cu-DOTAGA-PSMA-I&T and comparable to those of [68Ga]Ga-PSMA-11 and [18F]PSMA-1007 at 1 h after injection and increased significantly between 1 and 4 h after injection in most cases. Human dosimetry estimates for [61Cu]Cu-NODAGA-PSMA-I&T were similar to the ones reported for 18F-PSMA ligands. First-in-human imaging demonstrated multifocal osseous and hepatic metastases. Conclusion: [61Cu]Cu-NODAGA-PSMA-I&T is a promising PSMA radiotracer that compares favorably with [68Ga]Ga-PSMA-11 and [18F]PSMA-1007, while allowing delayed imaging.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Basaco Bernabeu T, Mansi R, Del Pozzo L, et al. 61Cu-PSMA-Targeted PET for Prostate Cancer: From Radiotracer Development to First-in-Human Imaging. J Nucl Med. 2024. PMID: 39025646. doi:10.2967/jnumed.123.267126

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。